Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Common Cancer Link May Unleash Potential of Antibodies

November 29, 2010
By Greg Frieherr
Greg Frieherr
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 11
Volume 19
Issue 11

The search for a magic bullet against cancer historically has glowed bright then dimmed, depending on the stage of discovery. Developments surrounding monoclonal antibodies and angiogenesis inhibitors have followed this cycle, as exuberance for their potential has bowed to the nuances that underlie the complex mechanisms on which they depend.

The search for a magic bullet against cancer historically has glowed bright then dimmed, depending on the stage of discovery. Developments surrounding monoclonal antibodies and angiogenesis inhibitors have followed this cycle, as exuberance for their potential has bowed to the nuances that underlie the complex mechanisms on which they depend.

Now a new possibility promises to light the cancer scene, one that might allow oncologists to finally realize the full potential of monoclonal antibodies and angiogenesis inhibitors.

An international research team has found a link among common types and grades of cancer: extraordinarily high concentrations of follicle-stimulating hormone (FSH) receptors in the blood vessels feeding these cancers. The only normal blood vessels on which FSH receptors appear are those in reproductive organs and then only in much lower concentrations than the investigators found on the blood vessels that feed tumors.

The research done at the Mount Sinai School of Medicine in New York, in collaboration with France's National Institute of Health and Medical Research, documented these high concentrations on blood vessel walls accompanying cancers of the prostate, breast, colon, pancreas, lung, liver, and ovaries.

Ultimately, the discovery could lead to the development of new diagnostics in MR, PET, or even ultrasound imaging, the researchers said. There is also potential for developing highly specific anticancer drugs.

Built around antibodies specific to FSH receptors, tumor imaging agents might be injected into the bloodstream, where they would selectively bind to the new marker to visualize early tumors, according to Aurelian Radu, PhD, an assistant professor of developmental and regenerative biology at Mount Sinai. These antibodies might also carry therapeutic agents to the tumors. One of the chief active components of these therapeutic agents is an antiangiogenesis agent.

The concept underlying antiangiogenesis as a cancer therapy is to slow or stop the growth of blood vessels that feed new tumor growth, thereby starving the tumor. Such efforts, however, have been complicated by the general nature of and the body's normal dependence on angiogenesis. The presence of FSH receptors promises to simplify oncology's attack plan (N Engl J Med 363:1621-1630, 2010).

New therapeutic agents might be tagged with antibodies specific to FSH receptors. Once injected into the bloodstream, they might bind to the FSH receptor in such a way as to block release of the vascular endothelial growth factor that stimulates the growth of blood vessels. Antibodies specific to the FSH receptor might even carry coagulants that clog the vascular beds that surround existing tumors or destroy these blood vessels, Dr. Radu said. The U.S.-French team evaluated tissue samples from the tumors of 1,336 people with any of the 11 most common cancer types and discovered high concentrations of FSH receptors on the blood vessels associated with all of these tissues, raising hopes that specific diagnostic and therapeutic agents can be developed.

Articles in this issue

Should maintenance therapy serve as the standard of care in metastatic non-small-cell lung cancer?
Should maintenance therapy serve as the standard of care in metastatic non-small-cell lung cancer?
Provenge wild ride blazes trail for immunotherapy
Provenge wild ride blazes trail for immunotherapy
Oncologists seek refuge from stalled  economy by joining forces
Oncologists seek refuge from stalled economy by joining forces
Lower Dose Chemotherapy Plus Radiation Offers  Favorable Prognosis in Hodgkin’s Lymphoma Patients
Lower Dose Chemotherapy Plus Radiation Offers Favorable Prognosis in Hodgkin’s Lymphoma Patients
Bevacizumab Offers New Hope to Ovarian Cancer Patients
Bevacizumab Offers New Hope to Ovarian Cancer Patients
BRCA Carriers Benefit From Mutations
BRCA Carriers Benefit From Mutations
From the ONI archives: Hereditary breast cancer patients benefit from multidisciplinary approach
From the ONI archives: Hereditary breast cancer patients benefit from multidisciplinary approach
From the ONI archives: Specialists contend with modest evidence on the value of adjuvant therapy
From the ONI archives: Specialists contend with modest evidence on the value of adjuvant therapy
Cultural values sway public risk perception of HPV vaccine
Cultural values sway public risk perception of HPV vaccine
Anti-viral drug demonstrates ability to retard growth of cervical cancer cells
Anti-viral drug demonstrates ability to retard growth of cervical cancer cells
Oncologists need to play a role in public education  on HPV vaccination
Oncologists need to play a role in public education on HPV vaccination
Handling incidental findings: the (less than) 1% solution
UCLA renews grant to find countermeasures to dirty bombs
CT Colonography and Telerad Meet Rural Screening Needs
CT Colonography and Telerad Meet Rural Screening Needs
Common Cancer Link May Unleash Potential of Antibodies
Common Cancer Link May Unleash Potential of Antibodies
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Advertisement

Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 21st 2025
Article

TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.

Low Dose-Averaged LET Exhibits Poor Local Control in Pancreatic Cancer

Roman Fabbricatore
August 20th 2025
Article

The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C-mutated colorectal cancer population.

Sotorasib Combo Improves Patient-Reported Outcomes in KRAS G12C+ CRC

Russ Conroy
August 17th 2025
Article

Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C–mutated colorectal cancer population.


An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors

Roman Fabbricatore
August 15th 2025
Article

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Related Content
Advertisement

Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 21st 2025
Article

TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.

Low Dose-Averaged LET Exhibits Poor Local Control in Pancreatic Cancer

Roman Fabbricatore
August 20th 2025
Article

The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C-mutated colorectal cancer population.

Sotorasib Combo Improves Patient-Reported Outcomes in KRAS G12C+ CRC

Russ Conroy
August 17th 2025
Article

Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C–mutated colorectal cancer population.


An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors

Roman Fabbricatore
August 15th 2025
Article

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.